Teaching Video NeuroImage: Disabling Jaw Clonus in a Bulbar-Onset ALS Patient Successfully Treated With Botulinum Toxin

Author(s):
Miguel Oliveira Santos, MD\textsuperscript{1,2}; Miguel Schön, MD\textsuperscript{1}; Anabela Valadas, MD\textsuperscript{1}; Mamede de Carvalho, MD, PhD\textsuperscript{1,2}

Corresponding Author:
Miguel Oliveira Santos, migueloliveirasantos@hotmail.com

Affiliation Information for All Authors: 1 - Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. 2 - Institute of Physiology, Instituto de Medicina Molecular-JLA, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Equal Author Contribution:
Miguel Oliveira Santos and Miguel Schon contributed equally to this work.

Contributions:
Miguel Oliveira Santos: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: - - - - Schön - - Anabela Valadas - - Mamede de Carvalho
Miguel Schön: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: - - Oliveira Santos - - - - Anabela Valadas - - Mamede de Carvalho
Anabela Valadas: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: - - Miguel Oliveira Santos - - Miguel Schön - - - - Mamede de Carvalho
Mamede de Carvalho: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: - - Miguel Oliveira Santos - - Miguel Schön - - Anabela Valadas -

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes. Videos, if applicable, will be available when the article is published in its final form.
Jaw clonus is a rare neurological finding associated with supranuclear lesions of the trigeminal nerve. It is rare in amyotrophic lateral sclerosis (ALS) [1]. We describe a 63-year-old ALS patient who presented with a disabling and sustained jaw clonus, reduced by mouth resting and elicited by mouth opening (video-1). Association of baclofen (25 mg/3id), tizanidine (2 mg/id) and benzodiazepine treatments were ineffective. Onabotulinum toxin A injections were administered into temporal (13 units) and masseter (25 units) muscles, bilaterally. She experienced a complete relief of her symptom up to 4-5 months, with no side-effects (video-2). She confirmed quality of life improving.
References


Video Title

A disabling and sustained jaw clonus before (video-1) and 4 months after onabotulinum toxin A treatment (video-2).
Teaching Video NeuroImage: Disabling Jaw Clonus in a Bulbar-Onset ALS Patient Successfully Treated With Botulinum Toxin
Miguel Oliveira Santos, Miguel Schön, Anabela Valadas, et al.
Neurology published online August 25, 2022
DOI 10.1212/WNL.0000000000201114

This information is current as of August 25, 2022